Drug interactions
Rimegepant + Tucatinib
Severity: Major
Rimegepant and Tucatinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tucatinib inhibits CYP3A4 and may substantially raise rimegepant exposure. This increases the risk of dose-related adverse effects.
What this interaction means in plain words
Rimegepant and Tucatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Rimegepant belongs to Central Nervous System; Tucatinib belongs to Oncology.
Why it happens
Tucatinib inhibits CYP3A4 (and P-gp), reducing rimegepant clearance.
What to do
Avoid concurrent use. If unavoidable, avoid a second rimegepant dose within 48 hours and monitor for adverse effects.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Rimegepant and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Rimegepant
Other interactions of Tucatinib
- Cisapride + Tucatinib Contraindicated
- Eletriptan + Tucatinib Contraindicated
- Ergotamine + Tucatinib Contraindicated
- Flibanserin + Tucatinib Contraindicated
- Ranolazine + Tucatinib Contraindicated
- Amobarbital + Tucatinib Major
Frequently asked questions
Can I take Rimegepant with Tucatinib?
MediHelp rates the interaction as major. Rimegepant and Tucatinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Tucatinib inhibits CYP3A4 and may substantially raise rimegepant exposure. This increases the risk of dose-related adverse effects.
How serious is the interaction between Rimegepant and Tucatinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use. If unavoidable, avoid a second rimegepant dose within 48 hours and monitor for adverse effects.
What other medicines interact with Rimegepant?
MediHelp also lists interactions of Rimegepant with, for example, Amobarbital, Atazanavir, Butabarbital. The full list is on the Rimegepant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
